# Dosing & Timing **Dosing and Timing for Polydatin** **Important context before reading this section:**\ Optimal therapeutic doses of polydatin in humans with active cancer have not been established in clinical trials. What follows draws on human safety and pharmacokinetic data, resveratrol translational literature, and the doses used in the limited available human studies. This section is intended to help members become better informed, to the extent possible, not to recommend a specific dose. **What the human safety data tells us** Human studies using standard polydatin have tested doses ranging from 40 mg up to 1,200 mg per day without significant adverse effects reported. A Phase I human study of resveratrol (polydatin's direct metabolite) established that doses of up to 5,000 mg/day were tolerated in healthy volunteers, with mild gastrointestinal effects at the higher end — this gives some translational safety ceiling guidance, bearing in mind polydatin converts to resveratrol at a fraction of the molar dose. No maximum tolerated dose (MTD) has been formally identified for polydatin in humans, indicating that clinical dose-escalation studies have not yet defined an upper safety boundary for polydatin in cancer patients. **Why the MCS Formulas Liposomal Pro 100 mg/day is likely a wellness or longevity dose, not a therapeutic oncology dose** The 100 mg dose in a product like MCS Formulas Polydatin Pro Liposomal reflects a sensible, commercially conservative formulation positioned at the longevity and health-maintenance end of the spectrum. In preclinical cancer research, the doses that produced meaningful anticancer effects — G6PD inhibition, induction of apoptosis, tumour reduction — were typically in the range of 50–200 mg/kg in animal models. Direct translation of animal doses to human equivalent doses (HED) using standard body surface area conversion (dividing by 6.2 for mouse-to-human) **suggests human equivalent doses in the range of roughly 500 mg to over 2,000 mg per day for a 70 kg adult — well above a standard 100 mg capsule.** One must keep in mind that pro-liposomal delivery meaningfully improves bioavailability — studies suggest 2 to 3 times higher absorption than standard formulations. A single [100 mg pro liposomal capsule](https://www.mcsformulas.com/vitamins-supplements/polydatin-pro-liposomal/ref/14) dose may deliver bioavailable polydatin comparable to perhaps 200–300 mg of a standard powder preparation. So one capsule is still likely below the level suggested by preclinical therapeutic modelling for active disease. Three pro liposomal capsules place one dose in the lower end of the therapeutic range for a 70kg adult. **Factors a clinician will consider when discussing dose:** * Whether the person is in active treatment, consolidation, or survivorship — dose rationale differs significantly across these phases * Hepatic and renal function — clearance pathways affect both safety and exposure * Drug interaction profile — particularly CYP3A4-metabolised agents, as discussed in the interactions section * Formulation used — liposomal or pro-liposomal formulations justify lower nominal doses than standard powder * Combination context — if polydatin is being used alongside other PPP-targeting or redox-active compounds, the cumulative effect needs consideration * Platelet function and bleeding risk — relevant at higher doses in thrombocytopenic patients **Bottom line for group members** 100 mg/day of a high-quality pro-liposomal polydatin is a reasonable and safe starting point and may be appropriate for prevention, survivorship, or general adjunctive support. For members with active disease exploring polydatin as part of a more targeted metabolic or PPP-disruption strategy, the preclinical and translational literature suggests substantially higher doses may be needed to reach mechanistically relevant tissue concentrations — and this conversation belongs with an integrative oncology clinician who can review the full clinical picture for the individual. **References for Dosing Considerations** * Phase I pharmacokinetic and pharmacodynamic study of resveratrol, a chemopreventive agent, in healthy volunteers with repeat-dose administration: * Comparative pharmacokinetics and tissue distribution of polydatin and its metabolite resveratrol following oral administration: * Improved bioavailability of polydatin and its protective effect against cisplatin-induced acute kidney injury: * Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/dosing-and-timing.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.